107 related articles for article (PubMed ID: 15474322)
1. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.
LaPlante KL; Rybak MJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):125-30. PubMed ID: 15474322
[TBL] [Abstract][Full Text] [Related]
2. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
Akins RL; Rybak MJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1925-9. PubMed ID: 10858356
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin.
Stuart JI; John MA; Milburn S; Diagre D; Wilson B; Hussain Z
Int J Antimicrob Agents; 2011 Mar; 37(3):248-52. PubMed ID: 21295951
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
9. ANTI-ADHESIVE AND ANTI-BIOFILM ACTIVITIES IN VITRO OF LINEZOLID, VANCOMYCIN, TIGECYCLINE AND DAPTOMYCIN AGAINST STAPHYLOCOCCUS HAEMOLYTICUS.
Juda M; Helon P; Malm A
Acta Pol Pharm; 2016 Nov; 73(6):1539-1543. PubMed ID: 29634108
[TBL] [Abstract][Full Text] [Related]
10. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
Rose WE; Poppens PT
J Antimicrob Chemother; 2009 Mar; 63(3):485-8. PubMed ID: 19109338
[TBL] [Abstract][Full Text] [Related]
11. Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model.
Ozturk B; Gunay N; Ertugrul BM; Sakarya S
Can J Microbiol; 2016 Sep; 62(9):735-43. PubMed ID: 27295353
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus.
Watanabe T; Ohashi K; Matsui K; Kubota T
J Antimicrob Chemother; 1997 Apr; 39(4):471-6. PubMed ID: 9145819
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.
Denis O; Deplano A; Nonhoff C; Hallin M; De Ryck R; Vanhoof R; De Mendonça R; Struelens MJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2680-5. PubMed ID: 16870758
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.
Petersen PJ; Bradford PA; Weiss WJ; Murphy TM; Sum PE; Projan SJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2595-601. PubMed ID: 12121938
[TBL] [Abstract][Full Text] [Related]
15. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin.
Aoki Y
Jpn J Antibiot; 1994 Jun; 47(6):640-6. PubMed ID: 8072172
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus.
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):212-4. PubMed ID: 22608137
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
